PMID- 37265502
OWN - NLM
STAT- MEDLINE
DCOM- 20230605
LR  - 20230605
IS  - 2235-2988 (Electronic)
IS  - 2235-2988 (Linking)
VI  - 13
DP  - 2023
TI  - Amphotericin B colloidal dispersion: an effective drug for the treatment of 
      mucormycosis in China.
PG  - 1147624
LID - 10.3389/fcimb.2023.1147624 [doi]
LID - 1147624
AB  - OBJECTIVE: Mucormycosis has emerged as an increasingly important cause of 
      morbidity and mortality in immunocompromised patients, but the effective drugs 
      for the treatment are limited. Hence, the study aimed to summarize the 
      characteristics of mucormycosis in patients with hematological malignancies, and 
      investigate the efficacy and safety of Amphotericin B Colloidal Dispersion (ABCD) 
      in treating mucormycosis. METHODS: In this study, patients with mucormycosis 
      complicated by hematological malignancies who received ABCD at the First 
      Affiliated Hospital of Zhengzhou University from April 2021 to May 2022 were 
      retrospectively enrolled. The clinical data of the enrolled patients were 
      collected, and then, the drug response at 2 weeks, 4 weeks, and the end of 
      treatment; the survival rate at 4, 8, and 12 weeks; and the laboratory-related 
      indicators and adverse events (AEs) associated with ABCD were evaluated. RESULTS: 
      In total, 9 patients with mucormycosis complicated by hematological malignancies 
      were enrolled. The main symptoms were fever, cough, and chest pain. In addition, 
      reversed halo signs (RHS) were found on chest CTs. The responses to ABCD at 2 
      weeks, 4 weeks, and the end of treatment were 100% (9/9), 77.8% (7/9), and 77.8% 
      (7/9), respectively. The survival rates of the patients at 4, 8, and 12 weeks 
      were 77.8% (7/9), 66.7% (6/9), and 66.7% (6/9), respectively. Among 
      laboratory-related indicators, white blood cell (WBC) counts were significantly 
      increased from baseline after 1 and 2 weeks of ABCD treatment (P<0.05), whereas 
      neutrophil counts were only increased significantly from baseline at 2 weeks 
      post-treatment (P<0.05). The most common AEs were infusion-related AEs 
      manifesting as fever, chills, and pruritus. Moreover, none of the patients 
      suffered from renal injury once again. CONCLUSION: ABCD is a promising treatment 
      strategy for patients with mucormycosis complicated by hematologic malignancies, 
      showing remarkable efficacy and safety.
CI  - Copyright (c) 2023 Liu and Ma.
FAU - Liu, Juntao
AU  - Liu J
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, Henan, China.
FAU - Ma, Xiaoxu
AU  - Ma X
AD  - Department of Respiration, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, Henan, China.
LA  - eng
PT  - Journal Article
DEP - 20230517
PL  - Switzerland
TA  - Front Cell Infect Microbiol
JT  - Frontiers in cellular and infection microbiology
JID - 101585359
RN  - 7XU7A7DROE (Amphotericin B)
RN  - 0 (Antifungal Agents)
SB  - IM
MH  - Humans
MH  - Amphotericin B/adverse effects
MH  - Antifungal Agents/adverse effects
MH  - *Mucormycosis/drug therapy/chemically induced
MH  - Retrospective Studies
MH  - China
MH  - *Hematologic Neoplasms/complications/chemically induced/drug therapy
PMC - PMC10230081
OTO - NOTNLM
OT  - amphotericin B colloidal dispersion
OT  - efficacy
OT  - hematological malignancies
OT  - mucormycosis
OT  - safety
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/06/02 13:15
MHDA- 2023/06/05 06:42
PMCR- 2023/01/01
CRDT- 2023/06/02 10:44
PHST- 2023/01/19 00:00 [received]
PHST- 2023/05/02 00:00 [accepted]
PHST- 2023/06/05 06:42 [medline]
PHST- 2023/06/02 13:15 [pubmed]
PHST- 2023/06/02 10:44 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fcimb.2023.1147624 [doi]
PST - epublish
SO  - Front Cell Infect Microbiol. 2023 May 17;13:1147624. doi: 
      10.3389/fcimb.2023.1147624. eCollection 2023.